Condition
Idiopathic Peripheral Neuropathy
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Terminated1
Completed1
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06614322Phase 2Recruiting
SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.
NCT03401073Phase 2Completed
IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3
NCT01288937Phase 3TerminatedPrimary
A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
Showing all 3 trials